N,N-diethylcyclophosphamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 100460 |
| MeSH ID | M0119601 |
| Synonym |
|---|
| nsc-303263 |
| 2h-1,2-oxazaphosphorin-2-amine, n,n-diethyltetrahydro-, 2-oxide |
| 53859-37-3 |
| nsc303263 |
| n,n-diethylcyclophosphamide |
| dechlorcyclophosphamide |
| 2-(diethylamino)-tetrahydro-2h-1,3,2-oxazaphosphorine-2-oxide |
| asta b 516 |
| 2h-1,3,2-oxazaphosphorine, tetrahydro-2-(diethylamino)-, 2-oxide |
| b 516 |
| 2h-1,3,2-oxazaphosphorin-2-amine, n,n-diethyltetrahydro-, 2-oxide |
| brn 1073314 |
| 2-(diethylamino)tetrahydro-2h-1,3,2-oxazaphosphorine 2-oxide |
| tetrahydro-2-(diethylamino)-2h-1,3,2-oxazaphosphorine 2-oxide |
| 2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-n,n-diethyl-, 2-oxide |
| nsc 303263 |
| didechlorocyclophosphamide |
| asta 7019 |
| dedichlorocyclophosphamide |
| diethylcyclophosphamide |
| 2-(diethylamino)-1,3,2-oxazaphosphinane 2-oxide |
| asta-7019 |
| PC4BQ4V6GR |
| n,n-diethyl-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cyclophosphamide (CP) is selectively toxic to avian and mammalian B lymphocytes, but the mechanisms of action are incompletely understood." | ( Cytogenetic mechanisms in the selective toxicity of cyclophosphamide analogs and metabolites towards avian embryonic B lymphocytes in vivo. Bloom, SE; Colvin, OM; Wilmer, JL, 1992) | 0.28 |
| " The greater potency of PMC and T4P compared to CPA is likely the result of these compounds bypassing important detoxification steps, therefore, more of the parent compound reaches the ovary as the toxic metabolite." | ( Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Mattison, DR; Plowchalk, DR, 1991) | 0.28 |
| " Since diet and many drugs (including cyclophosphamide itself) are known to affect glutathione levels, the present studies suggest that cardiac and skeletal muscle glutathione content is likely to be a clinically significant determinant of the frequency and severity of the adverse drug interactions and systemic toxicity sometimes observed during cyclophosphamide therapy." | ( Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Aisaka, K; Bossen, EH; Colvin, OM; Friedman, HS; Gross, SS; Hilton, J; Levi, R; Popp, J; Powell, JB; Reimer, KA, 1990) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||